Ascendiant Capital initiated coverage on Daxor with a new price target
$DXR
Medical/Dental Instruments
Health Care
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
Save time and jump to the most important pieces.
Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA.), advancing its mission to optimize healthcare through precise fluid management. The new Daxor BVA device represents a significant leap forward in diagnostic technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume. Unlike its predecessor, the Daxor BVA-100™ system, this innovative analyzer is engineered to be: Three time
BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces excellent visibility of Daxor's technology at the premier global cardiology conference, the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. New data presented from Duke University Medical Center confirmed blood volume analysis (BVA) as a more precise measure of congestion in heart failure patients along with a focus session on the value of BVA
Regional Medical Leaders Embrace Daxor's ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into three regional healthcare facilities across the U.S. These facilities will use Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility equipped with state-of-the-art technology. The ezBVA Lab delivers comprehensive blood volume analysis (BVA) results within 24 hours for both inpatient and outpatient settings, improving patient outcomes while reducing costs. Recent sales wins include: A prominent Midwest academic medical center has inte
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
N-CEN - DAXOR CORP (0000027367) (Filer)
N-CSR - DAXOR CORP (0000027367) (Filer)
N-PX - DAXOR CORP (0000027367) (Filer)
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw." — Anonymous As we forge ahead into this pivotal year, Daxor remains laser-focused on our mission, unwavering in our execution of strategic goals, and fueled by the relentless determination for transformative growth and adoption of our technology. 2024 was remarkable for the
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4/A - DAXOR CORP (0000027367) (Issuer)
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe
Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4/A - DAXOR CORP (0000027367) (Issuer)